drugset / Trial / NCT03817528
ITI-007 (Lumateperone Tosylate) for Schizophrenia
Phase 2
Terminated
4 enrolled
New York State Psychiatric Institute
Intra-Cellular Therapies, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to offer open label ITI-007 treatment to patients who poorly respond or poorly tolerate approved medications.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2020-09-23
- Completion
- 2020-09-23
Outcome
Outcome not reported
Stopped: “ITI-007 approved by FDA”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumateperone | Small molecule | 40 mg | — |
| Subject | Lumateperone | Small molecule | 60 mg | — |